Real-World Galcanezumab Reduces Migraine Days by 7 Per Month with Over 60% Responder Rate | Research

The takeaway

Real-world meta-analysis of 36 studies shows galcanezumab reduces monthly migraine days by ~7 within the first month, with over 60% of patients achieving ≥50% reduction by 3 months.

~7 fewer migraine days/month
Real-world galcanezumab effectiveness within 1 month, with continued improvement through 12 months

What the researchers found

At 1 month: MMD reduction -6.93 days, HIT reduction -7.96 points. Over 60% achieved ≥50% MMD/MHD reduction within 3 months. Effects gradually increased through 12 months. AE rates 25% (6 months) to 35% (12 months).

Why it matters

Real-world data confirms galcanezumab works outside of ideal trial conditions, giving clinicians and patients confidence in this anti-CGRP therapy.

How the study worked

Systematic review and meta-analysis of 36 real-world studies from PubMed, Scopus, and Web of Science through February 2025, with pooled proportions and mean differences.

What this study cannot tell us

Significant heterogeneity across studies. No randomization or control groups in most studies. Potential publication bias. Variable outcome measurement across studies.

How to read the evidence

Systematic review of 36 real-world studies. Strong evidence base but limited by heterogeneity and absence of controlled comparisons.

When this study was published

Published in 2025 with studies through February 2025.

The bigger picture

This is the most comprehensive real-world evidence compilation for galcanezumab, confirming the clinical trial promise translates to everyday practice.

Questions still open

How does galcanezumab's real-world effectiveness compare to other anti-CGRP antibodies?
What predicts which patients will be super-responders?
Does effectiveness change beyond 12 months?

Common questions

Does galcanezumab work as well in real life as in clinical trials?

Yes, this analysis of 36 real-world studies shows galcanezumab reduces migraine days by about 7 per month, with over 60% of patients experiencing at least half as many migraines within 3 months — results consistent with or better than clinical trials.

What are the side effects?

About 25-35% of patients experienced side effects, most commonly constipation. These were generally manageable, and the benefits significantly outweighed the side effects for most patients.

Read the original research

Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.

Headache, 66(1), 262-277

View on PubMed ↗Publisher’s paper ↗

Citation

Fernández-Bravo-Rodrigo, Jaime; Pascual-Morena, Carlos; Saz-Lara, Alicia; Martínez-García, Irene; Lever-Megina, Carla Geovanna; Patiño-Cardona, Silvana; Flor-García, Amparo; Cavero-Redondo, Iván. (2026). Real-world effectiveness and safety of galcanezumab for the treatment of migraine: A systematic review and meta-analysis.. Headache, 66(1), 262-277. https://doi.org/10.1111/head.70003